Novartis AG - Depositary Receipt (Common Stock)
US ˙ NYSE ˙ US66987V1098

SecurityNVS / Novartis AG - Depositary Receipt (Common Stock)
InstitutionGrimes & Company, Inc.
Latest Disclosed Ownership4,758 shares
Latest Disclosed Value $ 726,724
Grimes & Company, Inc. reports 2.59% increase in ownership of NVS / Novartis AG - Depositary Receipt (Common Stock)

On April 21, 2026 - Grimes & Company, Inc. filed a 13F-HR form disclosing ownership of 4,758 shares of Novartis AG - Depositary Receipt (Common Stock) (US:NVS) valued at $726,784 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 3, 2026 disclosing 4,638 shares of Novartis AG - Depositary Receipt (Common Stock). This represents a change in shares of 2.59% during the quarter. The current value of the position is $683,534 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-21 2026-03-31 13F NOVARTIS SPONSORED ADR 66987V109 4,758 120 2.59 727 13.62 0.0201
2026-02-03 2025-12-31 13F NOVARTIS SPONSORED ADR 66987V109 4,638 287 6.60 639 14.52 0.0153
2025-10-27 2025-09-30 13F NOVARTIS SPONSORED ADR 66987V109 4,351 -177 -3.91 558 2.01 0.0138
2025-07-22 2025-06-30 13F NOVARTIS SPONSORED ADR 66987V109 4,528 -94 -2.03 548 6.21 0.0149
2025-04-17 2025-03-31 13F NOVARTIS SPONSORED ADR 66987V109 4,622 135 3.01 515 18.12 0.0159
2025-01-21 2024-12-31 13F NOVARTIS SPONSORED ADR 66987V109 4,487 -84 -1.84 437 -16.95 0.0126
2024-10-22 2024-09-30 13F NOVARTIS SPONSORED ADR 66987V109 4,571 16 0.35 526 8.47 0.0142
2024-07-22 2024-06-30 13F NOVARTIS SPONSORED ADR 66987V109 4,555 -9,967 -68.63 485 -65.53 0.0145
2024-04-17 2024-03-31 13F NOVARTIS SPONSORED ADR 66987V109 14,522 -478 -3.19 1,405 -7.27 0.0432
2024-01-24 2023-12-31 13F NOVARTIS SPONSORED ADR 66987V109 15,000 -785 -4.97 1,515 -5.79 0.0501
2023-10-19 2023-09-30 13F NOVARTIS SPONSORED ADR 66987V109 15,785 -1,426 -8.29 1,608 -7.43 0.0622
2023-07-19 2023-06-30 13F NOVARTIS SPONSORED ADR 66987V109 17,211 -121,877 -87.63 1,737 -86.43 0.0616
2023-04-20 2023-03-31 13F NOVARTIS SPONSORED ADR 66987V109 139,088 -3,603 -2.53 12,796 -1.14 0.5244
2023-01-25 2022-12-31 13F NOVARTIS SPONSORED ADR 66987V109 142,691 45 0.03 12,945 19.38 0.5465
2022-10-28 2022-09-30 13F NOVARTIS SPONSORED ADR 66987V109 142,646 1,341 0.95 10,843 -9.23 0.5658
2022-07-22 2022-06-30 13F NOVARTIS SPONSORED ADR 66987V109 141,305 2,347 1.69 11,945 -2.03 0.6023
2022-05-06 2022-03-31 13F NOVARTIS SPONSORED ADR 66987V109 138,958 48,186 53.08 12,193 53.56 0.5696
2022-05-06 2022-03-31 13F NOVARTIS SPONSORED ADR 66987V109 137,222 12,041
2022-02-01 2021-12-31 13F NOVARTIS SPONSORED ADR 66987V109 90,772 2,205 2.49 7,940 9.62 0.3634
2021-11-08 2021-09-30 13F NOVARTIS SPONSORED ADR 66987V109 88,567 2,696 3.14 7,243 -7.56 0.3152
2021-08-04 2021-06-30 13F NOVARTIS SPONSORED ADR 66987V109 85,871 1,787 2.13 7,835 9.00 0.3399
2021-05-12 2021-03-31 13F NOVARTIS SPONSORED ADR 66987V109 84,084 2,631 3.23 7,188 -6.55 0.3457
2021-02-02 2020-12-31 13F Novartis COM 66987V109 81,453 1,477 1.85 7,692 10.61 0.3996
2020-11-12 2020-09-30 13F Novartis COM 66987V109 79,976 12,186 17.98 6,954 17.45 0.4448
2020-07-31 2020-06-30 13F Novartis COM 66987V109 67,790 -673 -0.98 5,921 4.89 0.4114
2020-05-05 2020-03-31 13F Novartis COM 66987V109 68,463 224 0.33 5,645 -12.64 0.5152
2020-02-05 2019-12-31 13F Novartis COM 66987V109 68,239 517 0.76 6,462 9.80 0.4234
2019-11-05 2019-09-30 13F Novartis COM 66987V109 67,722 1,170 1.76 5,885 -3.16 0.4193
2019-07-30 2019-06-30 13F Novartis COM 66987V109 66,552 1,754 2.71 6,077 -2.46 0.4612
2019-05-02 2019-03-31 13F Novartis COM 66987V109 64,798 58 0.09 6,230 12.15 0.4883
2019-02-01 2018-12-31 13F Novartis COM 66987V109 64,740 -721 -1.10 5,555 -1.52 0.5422
2018-11-09 2018-09-30 13F Novartis COM 66987V109 65,461 -17,950 -21.52 5,641 -10.47 0.4516
2018-08-10 2018-06-30 13F Novartis COM 66987V109 83,411 -730 -0.87 6,301 -7.38 0.5569
2018-05-07 2018-03-31 13F Novartis COM 66987V109 84,141 1,673 2.03 6,803 -1.75 0.6591
2018-02-05 2017-12-31 13F Novartis COM 66987V109 82,468 50,821 160.59 6,924 154.84 0.6683
2017-11-03 2017-09-30 13F Novartis COM 66987V109 31,647 -1,099 -3.36 2,717 -0.59 0.2889
2017-07-18 2017-06-30 13F Novartis COM 66987V109 32,746 -57,302 -63.63 2,733 -59.13 0.3049
2017-05-01 2017-03-31 13F Novartis COM 66987V109 90,048 9,719 12.10 6,687 14.27 0.7325
2017-01-24 2016-12-31 13F Novartis COM 66987V109 80,329 -4,507 -5.31 5,852 -12.64 0.6788
2016-10-24 2016-09-30 13F Novartis COM 66987V109 84,836 -2,808 -3.20 6,699 -7.37 0.8966
2016-07-25 2016-06-30 13F Novartis COM 66987V109 87,644 8,366 10.55 7,232 25.93 0.9665
2016-04-25 2016-03-31 13F Novartis COM 66987V109 79,278 -3,015 -3.66 5,743 -18.88 0.7388
2016-02-03 2015-12-31 13F Novartis COM 66987V109 82,293 81 0.10 7,080 -6.31 0.9561
2015-10-08 2015-09-30 13F Novartis COM 66987V109 82,212 -3,526 -4.11 7,557 -10.38 0.9723
2015-08-11 2015-06-30 13F Novartis COM 66987V109 85,738 719 0.85 8,432 0.57 1.1875
2015-04-24 2015-03-31 13F Novartis COM 66987V109 85,019 1,811 2.18 8,384 8.74 2.0153
2015-02-12 2014-12-31 13F Novartis COM 66987V109 83,208 -743 -0.89 7,710 -2.43 1.9929
2014-11-06 2014-09-30 13F Novartis COM 66987V109 83,951 -2,291 -2.66 7,902 1.20 2.0681
2014-07-28 2014-06-30 13F Novartis COM 66987V109 86,242 872 1.02 7,808 7.56 2.0457
2014-05-01 2014-03-31 13F Novartis COM 66987V109 85,370 3,083 3.75 7,259 9.75 2.0388
2014-02-03 2013-12-31 13F Novartis COM 66987V109 82,287 2,815 3.54 6,614 8.48 1.9766
2013-10-29 2013-09-30 13F Novartis COM 66987V109 79,472 3,767 4.98 6,097 13.90 2.0624
2013-07-30 2013-06-30 13F Novartis COM 66987V109 75,705 75,705 5,353 1.9522
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.